These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36581260)

  • 1. Polysaccharide-based nanocarriers for efficient transvascular drug delivery.
    Zhang M; Ma H; Wang X; Yu B; Cong H; Shen Y
    J Control Release; 2023 Feb; 354():167-187. PubMed ID: 36581260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
    Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
    Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transvascular transport of nanocarriers for tumor delivery.
    Li X; Hu Y; Zhang X; Shi X; Parak WJ; Pich A
    Nat Commun; 2024 Sep; 15(1):8172. PubMed ID: 39289401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcytosis-enabled active extravasation of tumor nanomedicine.
    Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
    Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of natural products via polysaccharide-based nanocarriers for cancer therapy: A review on recent advances and future challenges.
    Jiang Y; Yan C; Li M; Chen S; Chen Z; Yang L; Luo K
    Int J Biol Macromol; 2024 Oct; 278(Pt 4):135072. PubMed ID: 39191341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Cancer Drug Delivery Using Carbohydrate-Based Polymers.
    Ranjbari J; Mokhtarzadeh A; Alibakhshi A; Tabarzad M; Hejazi M; Ramezani M
    Curr Pharm Des; 2018 Feb; 23(39):6019-6032. PubMed ID: 28482782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transport barriers and strategies of antitumor nanocarriers delivery system.
    Zhang L; Wang Y; Cao Y; Lou D; Wang B
    J Biomed Mater Res A; 2013 Dec; 101(12):3661-9. PubMed ID: 23983207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.
    Acharya S; Sahoo SK
    Adv Drug Deliv Rev; 2011 Mar; 63(3):170-83. PubMed ID: 20965219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
    Koning GA; Krijger GC
    Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming key biological barriers to cancer drug delivery and efficacy.
    Kim SM; Faix PH; Schnitzer JE
    J Control Release; 2017 Dec; 267():15-30. PubMed ID: 28917530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor delivery of macromolecular drugs based on the EPR effect.
    Torchilin V
    Adv Drug Deliv Rev; 2011 Mar; 63(3):131-5. PubMed ID: 20304019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
    Greish K
    J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation.
    Ikeda-Imafuku M; Wang LL; Rodrigues D; Shaha S; Zhao Z; Mitragotri S
    J Control Release; 2022 May; 345():512-536. PubMed ID: 35337939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of tumor microenvironment for improved delivery and intratumor distribution of nanocarriers.
    Ishida T; Kiwada H
    Biol Pharm Bull; 2013; 36(5):692-7. PubMed ID: 23649327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcytosis - An effective targeting strategy that is complementary to "EPR effect" for pancreatic cancer nano drug delivery.
    Liu X; Jiang J; Meng H
    Theranostics; 2019; 9(26):8018-8025. PubMed ID: 31754378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles.
    Souri M; Soltani M; Moradi Kashkooli F; Kiani Shahvandi M
    J Control Release; 2022 Jan; 341():227-246. PubMed ID: 34822909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming multiple gastrointestinal barriers by bilayer modified hollow mesoporous silica nanocarriers.
    Wang Y; Zhao Y; Cui Y; Zhao Q; Zhang Q; Musetti S; Kinghorn KA; Wang S
    Acta Biomater; 2018 Jan; 65():405-416. PubMed ID: 29037897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy.
    Wu H; Li W; Hao M; Wang Y; Xue L; Ju C; Zhang C
    Adv Drug Deliv Rev; 2022 Aug; 187():114380. PubMed ID: 35662610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of chitosan-based nanocarriers in tumor-targeted drug delivery.
    Ghaz-Jahanian MA; Abbaspour-Aghdam F; Anarjan N; Berenjian A; Jafarizadeh-Malmiri H
    Mol Biotechnol; 2015 Mar; 57(3):201-18. PubMed ID: 25385004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect.
    Huang D; Sun L; Huang L; Chen Y
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.